EAM Investors’s Pacira BioSciences PCRX Stock Holding History

EAM Investors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-45,145	Closed	-$3.44M	–	327
2022 Q1	$3.44M	Buy	+45,145	New	+$3.01M	0.64%	23
2020 Q4	–	Sell	-26,798	Closed	-$1.61M	–	367
2020 Q3	$1.61M	Sell	26,798 -10,339	-28%	-$601K	0.38%	91
2020 Q2	$1.95M	Buy	+37,137	New	+$1.55M	0.43%	89
2016 Q1	–	Sell	-39,026	Closed	-$3M	–	328
2015 Q4	$3M	Buy	+39,026	New	+$2.21M	0.39%	116
2015 Q1	–	Sell	-20,604	Closed	-$1.83M	–	380
2014 Q4	$1.83M	Buy	20,604 +2,340	+13%	+$221K	0.25%	179
2014 Q3	$1.77M	Sell	18,264 -4,937	-21%	-$480K	0.36%	87
2014 Q2	$2.13M	Sell	23,201 -11,254	-33%	-$857K	0.4%	57
2014 Q1	$2.41M	Sell	34,455 -6,374	-16%	-$434K	0.43%	55
2013 Q4	$2.35M	Sell	40,829 -20,686	-34%	-$1.09M	0.42%	62
2013 Q3	$2.96M	Sell	61,515 -3,126	-5%	-$114K	0.59%	25
2013 Q2	$1.88M	Buy	+64,641	New	+$1.87M	0.41%	63

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

EAM Investors's PCRX Position: Q2 2022 in Review

EAM Investors sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 45,145 shares — an estimated $3.44M sold.

EAM Investors first reported a position in PCRX in Q2 2013 and held it in 11 quarters. The position peaked at $3.44M in Q1 2022. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

EAM Investors reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
EAM Investors sold 45,145 Pacira BioSciences shares in Q2 2022, an estimated $3.44M.
EAM Investors first reported a position in Pacira BioSciences in Q2 2013 and held it in 11 quarters.
EAM Investors's Pacira BioSciences position peaked at $3.44M in Q1 2022.
284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on EAM Investors's 13F filing for Q2 2022, filed 12 Aug 2022.